LUMIDENCE

Research & Life Sciences

LUMIDENCE

Research & Life Sciences

SCOPE

Define the decision

PROOF

Verify the evidence

POSITION

Compare what matters

IMPLICATION

Translate the findings

DEFINE · DISCOVER · SOURCE · VERIFY · STRUCTURE · CONNECT · INTERPRET · IMPLICATE

ABOUT LUMIDENCE

Externalevidenceisabundant.Decision-relevantintelligenceisn’t.

ENGAGEMENT FOCUS

ONE

Focused around one consequential asset decision.

INTELLIGENCE METHOD

STRUCTURED

Evidence organized around what matters to the decision.

QUESTION, EVIDENCE, ANALYSIS, IMPLICATION

Technology-assisted. Human-directed. Evidence-driven.

Q

E

A

I

EVIDENCE STANDARD

TRACEABLE

Primary evidence, supporting context, and decision-relevant interpretation.

DECISION OUTPUT

CLARITY

Findings translated into implications for the decision at hand.

EXPERTISE

FOCUSED INTELLIGENCE built around the decision — not a generic landscape.

FOCUSED INTELLIGENCE built around the decision — not a generic landscape.

FOCUSED INTELLIGENCE built around the decision — not a generic landscape.

One defined asset. One consequential decision. Intelligence focused on the evidence material to both.

Define the Asset Decision

Establish the decision question, asset scope, indication, and competitive context that will guide the engagement.

Focused Competitive Landscape

Evaluate the external scientific and competitive evidence material to the defined asset decision.

Decision Intelligence Brief

Translate verified findings into competitive implications relevant to the decision at hand.

WHEN TO ENGAGE

When the external landscape changes the decision.

When the external landscape changes the decision.

When the external landscape changes the decision.

New evidence, competitive movement, or an emerging signal can change what an asset team needs to understand.

READOUT

New Data Emerges

A competitor or the client asset reports data that could change the competitive picture.

READOUT

SHIFT

The Landscape Moves

A new program, mechanism, indication, or development changes the relevant competitive environment..

SIGNAL

Differentiation Emerges

A biomarker, patient-selection strategy, or clinical signal creates a potential point of differentiation.

REVIEW

REVIEW

A Decision Is Approaching

Leadership needs a clearer external evidence picture before an asset or portfolio discussion.

SELECTED INTELLIGENCE

See how Lumidence approaches an asset decision.

See how Lumidence approaches an asset decision.

See how Lumidence approaches an asset decision.

NEUROPSYCHIATRY

Precision MDD Competitive Landscape

Historical decision-point case study

EVIDENCE CUTOFF · JUNE 30, 2025

ALTO-203

Retail store interior

LANDSCAPE

COMPETITIVE SET

Precision- and biomarker-guided MDD programs

Mapping the landscape that matters

ALTO-203 CASE STUDY

OUR PRINCIPLE

Moreinformationisn’ttheobjective.Aclearerdecisionis.

Lumidence separates evidence from interpretation, verifies material findings against primary sources where available, and translates the external landscape into implications for the decision at hand.

Lumidence separates evidence from interpretation, verifies material findings against primary sources where available, and translates the external landscape into implications for the decision at hand.

EVIDENCE FIRST · DECISION RELEVANCE ALWAYS

What decision are you trying to make?

What decision are you trying to make?

What decision are you trying to make?

When an asset decision requires a clearer view of the external evidence, Lumidence can help define the intelligence question..

When an asset decision requires a clearer view of the external evidence, Lumidence can help define the intelligence question..

LUMIDENCE

Scientific and competitive intelligence for consequential asset decisions.

Resources

© 2026 Lumidence Research & Life Sciences. All rights reserved.

LUMIDENCE

Scientific and competitive intelligence for consequential asset decisions.

Resources

© 2026 Lumidence Research & Life Sciences. All rights reserved.

LUMIDENCE

Scientific and competitive intelligence for consequential asset decisions.

Resources

© 2026 Lumidence Research & Life Sciences. All rights reserved.